---
title: "Bristol-Myers Squibb (BMY) Gets a Hold from Scotiabank"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/301275241.md"
description: "Scotiabank analyst Louise Chen maintained a Hold rating on Bristol-Myers Squibb (BMY) with a $60 price target. While Cantor Fitzgerald also issued a Hold, J.P. Morgan kept its Buy rating on the stock."
datetime: "2026-10-08T12:16:18.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/301275241.md)
  - [en](https://longbridge.com/en/news/301275241.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/301275241.md)
generator: "portal-rs"
---

# Bristol-Myers Squibb (BMY) Gets a Hold from Scotiabank

In a report released today, Louise Chen from Scotiabank maintained a Hold rating on Bristol-Myers Squibb, with a price target of $60.00.

According to TipRanks, Chen is a 4-star analyst with an average return of 7.4% and a 53.61% success rate. Chen covers the Healthcare sector, focusing on stocks such as Johnson & Johnson, Merck & Company, and Amgen.

In addition to Scotiabank, Bristol-Myers Squibb also received a Hold from Cantor Fitzgerald’s Carter Gould in a report issued today. However, on the same day, J.P. Morgan maintained a Buy rating on Bristol-Myers Squibb (NYSE: BMY).

### Related Stocks

- [BMY.US](https://longbridge.com/en/quote/BMY.US.md)
- [AMGN.US](https://longbridge.com/en/quote/AMGN.US.md)
- [JPM.US](https://longbridge.com/en/quote/JPM.US.md)

## Related News & Research

- [Bristol-Myers Spokesperson Says Grade 5 Event That Was Disclosed As Part Of Data Disclosure At Ms Toronto Occurred After Trial Pause](https://longbridge.com/en/news/302909326.md)
- [Why Is Bristol-Myers Squibb (BMY) In Focus After New Phase 3 Myeloma Data?](https://longbridge.com/en/news/300448973.md)
- [7,129 Johnson & Johnson $JNJ Shares Sold by Smith Chas P & Associates PA Cpas](https://longbridge.com/en/news/302983370.md)
- [SBI Securities Co. Ltd. Acquires 10,021 Shares of Johnson & Johnson $JNJ](https://longbridge.com/en/news/302983364.md)
- [BUZZ-Bristol Myers rises on positive trial results for cancer and lung disease drugs](https://longbridge.com/en/news/301590676.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**